News and Trends 6 Nov 2018 First Potential Vaccine for Chikungunya Virus Flies Through Phase II The mosquito-borne chikungunya virus may one day have a vaccine, as an Austrian biotech’s lead candidate gets positive results in Phase II. Themis Bioscience measured the blood levels of antibodies against the company’s vaccine in 263 healthy volunteers. Four weeks after injections of its lead candidate vaccine, the participants had produced antibodies to protect themselves […] November 6, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 13 Sep 2018 Boehringer Ingelheim Acquires Oncolytic Virus Biotech Company Boehringer Ingelheim is paying €210M to acquire all the remaining shares of ViraTherapeutics, an Austrian biotech company developing oncolytic viral therapies for cancer. ViraTherapeutics develops cancer therapies based on viruses that selectively kill tumor cells, based on the principle that cancer cells show defective mechanisms to defend themselves against viruses that are not able to […] September 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Aug 2018 First 3D Placenta Model Helps Study Pregnancy Disorders Austrian researchers have created a miniature 3D model of the human placenta, which could help us understand the causes of pregnancy complications. The human placenta plays a vital role in maintaining a healthy pregnancy, supplying the fetus with the nutrients and hormones it needs to grow and protecting it from bacterial infections. Researchers at the […] August 7, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 7 Aug 2018 Update: Seaweed-Derived Treatment for Common Cold Approved in the EU Update (07/08/2018): Marinomed Biotech has obtained EU approval to sell a nasal spray containing a polymer derived from red seaweed that can trap most common cold viruses to stop them from infecting us. Published on 19/07/2018 Marinomed Biotech’s antiviral treatment, which is derived from seaweed, could be used to treat the cause of respiratory […] August 7, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2018 Austrian Researchers Grow Cancerous Mini Brains in a Dish Researchers in Vienna are growing mini brains that mimic the onset and development of brain cancer, which could be used to compare the efficacy of different treatments. Because of their cellular complexity, brain cancers have been difficult to study in animals. Glioblastoma, the most aggressive form of brain cancer, is particularly difficult to treat because […] July 25, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jun 2018 A Chip Could Help Us Identify Wheeze-Causing Types of Viruses Researchers in Vienna have developed a chip that identifies cold viruses that cause flare-ups of respiratory conditions such as asthma. The technology could help identify culprit viruses and help those affected take the best preventive and treatment measures. The chip, created by researchers at the Medical University of Vienna, uses a small blood sample to […] June 19, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 14 Feb 2018 This Biotech Veteran Is Using These Tips for Successful Drug Development, Here Is Why Our second interview at Refresh in Vienna was with Peter Llewellyn-Davies, the founder of Accellerate Partners and Apeiron’s CFO and CBO. He told us how he found himself at the biotech and shared the lessons he learned on his way there. Peter Llewellyn-Davies founded Accellerate Partners in 2012, which offers services including corporate expansion, funding […] February 14, 2018 - 5 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 7 Feb 2018 Hookipa CEO “Sleeps Quite Well at Night” with €50M Cash Pile and Cancer Vaccine Progress Did you miss us in Vienna? Here’s the first of our two interviews from the Refresh meetup last month: Jörn Aldag, CEO of Hookipa, talked to us about the importance of a sound financial strategy and where cancer vaccines are on the hype curve. Jörn Aldag has had quite a career. His first position as […] February 7, 2018 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2018 The Construction of an Industrial Algae Production Plant Begins in Austria BDI-BioEnergy produces algae for the food, pharma, and cosmetics industries. Now, it will build an industrial production plant to house its technology. BDI-BioEnergy is a specialized plant engineering company based in Styria, Austria. On Saturday, the company signaled the start of the construction of an industrial plant that will use its photobioreactor system to produce algae biomass. […] January 30, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2017 Someone’s Popular! Gilead is Just One Big Name Investing in this Vaccine Biotech Gilead has joined a growing list of powerful investors that want to help Hookipa Biotech develop its vaccine technology by participating in its Series C fundraising. Hookipa Biotech, one of October’s biotechs of the week, develops vaccines for cancer and infectious diseases. Its pipeline includes two platforms: Vaxwave and TheraT, which are targeted at cytomegalovirus infections and […] December 14, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 27 Nov 2017 Picking the Perfect Time to Strike: How to Stop HIV in its Tracks In the early stages of infection, the immune system might be able to stop HIV. Austrian researchers have taken a closer look to see what can be done before it’s too late. There has been no shortage of research to find an effective treatment or cure for HIV/AIDS, which affects over 36 million people. Austrian researchers at the […] November 27, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 6 Nov 2017 Austrian Biotech’s Vaccine Against Tropical Virus Moves Nicely Through Phase II Chikungunya fever could be the next big global outbreak. Reassuringly, Themis’ vaccine has so far performed well in a Phase II study. Vienna-based biotech, Themis, develops urgently needed vaccines against diseases, which have the potential to be the next global outbreak. The company has announced encouraging preliminary Phase II results for its vaccine against chikungunya […] November 6, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email